are questionnaires that measure concepts such as symptoms, satisfaction with appearance, and health-related quality of life. 2 Such measures were initially designed for use in academic and industry research but are increasingly being used for other purposes, including clinical care, patient/consumer education, benchmarking, and quality improvement. 3 For example, in the United Kingdom, the BREAST-Q, which measures satisfaction and health-related quality of life, was included in a voluntary nationwide audit of over 8000 mastectomy and breast reconstruction patients treated between 2008 and 2009. 4 A literature review commissioned by the United Kingdom Department of Health and published in 2013 5 identified that there are nine patient-reported outcome instruments for cosmetic treatments developed with patient input that have demonstrated adequate psychometric properties. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Of these nine, the review authors stated that only three meet current recommendations for the development and validation of patient-reported outcome instruments (i.e., BREAST-Q, 8, 9 FACE-Q, 13 and Skindex 16 ). The review concluded that research dedicated to the evaluation of patient-reported outcome instruments in cosmetic surgery is urgently required.
The FACE-Q encompasses a set of more than 40 independently functioning scales and checklists measuring concepts and symptoms important to facial aesthetic patients in relation to different facial areas (Table 1) . FACE-Q scales can be administered to any facial aesthetic patient (surgical and nonsurgical) to measure what patients think about their appearance, quality of life, adverse effects, and process of care. Each scale provides a standalone score from 0 to 100, with higher scores indicating a better outcome. Depending on the surgical or nonsurgical procedure, only those FACE-Q scales and/or checklists relevant to a particular patient or procedure(s) need be completed. Given the large number of FACE-Q scales addressing various facial anatomical areas and aspects of outcome, results for the scales are being published as a series of articles, each of which describes clinically relevant scale grouping (e.g., FACE-Q scales for face-lift patients) 17 and aspect of outcomes (satisfaction, health-related quality of life, adverse effect).
The aim of the present article is to describe the development and psychometric evaluation of FACE-Q scales that evaluate quality-of-life outcomes and decisional satisfaction. These include five scales (Psychological Wellbeing, Social 
METHODS

Development of FACE-Q Scales and Checklists
Ethics review board approval was obtained before starting the study. The FACE-Q was developed following internationally recommended guidelines for patient-reported outcome instruments. 2, [18] [19] [20] [21] The methods are described in detail elsewhere 13, 17, 22, 23 and described briefly below. In the first phase, we developed a conceptual framework using a mixed methods approach that involved a literature review, 24 expert input, and interviews with 50 patients who had undergone one or more surgical and/or nonsurgical facial aesthetic procedures. The framework includes four domains (appearance, quality of life, adverse effects, and process of care). The qualitative data were used to develop a comprehensive set of items, which in turn were used to form the set of FACE-Q scales. The following five scales and symptom checklist are described in this article:
1. Psychological Wellbeing. This scale measures psychological well-being in terms of a series of positively worded statements (e.g., "I feel happy"). Instructions ask that respondents answer with their facial appearance in mind and to think about the past week. Four response options are provided (i.e., definitely agree, somewhat agree, somewhat disagree, and definitely disagree 
Studies 2 and 3: Data Collection
Two companies used the Early Life Impact scale and the Recovery Early Symptom checklist in international clinical trials. Study 2 was a face-lift study where the scale and checklist were administered on days 2, 3 through 5, 7, and 30 after treatment. Study 3 was a minimally invasive lip treatment study where the scale and checklist were administered on days 1 and 14. From both studies, data collected in the first week after treatment (up to day 7) were used to develop and validate the Early Life Impact scale.
Study 2 also administered the Psychological Wellbeing and Social Function scales at baseline and days 14, 30, and 90, and the Satisfaction with Decision to Have Treatment and the Satisfaction with Outcome of Treatment scales on days 14, 30, and 90. Data from study 2 were included in the analysis to assess construct validity and responsiveness.
Data Analyses
The Recovery Early Symptom checklist data were examined descriptively in terms of the proportion of participants that answered to each response option on each posttreatment assessment day. Rasch measurement theory, 25, 26 conducted within RUMM2030 software (RUMM Laboratory, Perth, Australia), 27 was used to identify a set of items that represented the best indicators of outcome for each of the five scales. The analysis uses a number of statistical and graphic tests to examine each item in a scale. [28] [29] [30] The evidence is considered together to make decisions about the overall quality of a scale. When data fit the Rasch model, estimates from the model are considered appropriate because the measurement theory is supported by the data. The following tests and criteria were used by our team:
1. Thresholds for item response options: The use of response categories scored with successive integer scores implies a continuum (e.g., increasing psychological well-being). This assumption was tested by examining the ordering of thresholds, which are points of crossover between adjacent response categories (e.g., between somewhat disagree and somewhat agree). and is used to quantify error associated with the measurements of people in a sample.
Higher values indicate greater reliability.
Traditional psychometric tests 28 included the following: data quality (percentage missing data for each item), scaling assumptions (similarity of item means and variances, and magnitude and similarity of corrected item-total correlations), [32] [33] [34] scale-to-sample targeting (score means, standard deviation, and floor and ceiling effects), and internal consistency reliability (Cronbach alpha   31 and homogeneity coefficients). 35 The following aspects of construct validity were assessed to examine scale performance:
1. We correlated scores for the five scales to determine the extent to which they measured separate but related constructs. 36 We hypothesized that these intercorrelations would range between r = 0.30 and r = 0.70, as these scales were developed to measure distinct but related clinical variables. 37 2. We correlated scores for five scales with patient characteristics [i.e., age, sex, and ethnicity (where available)] to determine the extent to which a scale may be susceptible to bias by these sociodemographic variables. We predicted that these correlations would be low (<0.30). 38, 39 3. We computed a new variable to represent the total number of symptoms (zero to 17) on the Recovery Early Symptom checklist and correlated this with the Early Life Impact of Treatment scale score. We hypothesized that more symptoms would correlate with lower Early Life Impact of Treatment scores (i.e., worse health-related quality of life during recovery).
We examined responsiveness by comparing mean Rasch-transformed scores using analysis of variance and t-test statistics, and computing the effect sizes as described by Kazis et al. 40 and standardized response means. 41 The magnitude of the change for the latter two indicators of change can be interpreted using Cohen's arbitrary criteria (i.e., small, 0.20; moderate, 0.50; and large, 0.80). A minimally importance difference was calculated as a half standard deviation of the pretreatment mean score and by extrapolation of a change score based on a 0.5 effect size. 42 
RESULTS
In study 1, 228 participants were recruited faceto-face, of whom 220 responded (response rate, 96.5 percent); 199 participants were recruited by mail, and 103 responded (response rate, 51.7 percent). The overall response rate was 75.6 percent. Table 2 lists characteristics of the 702 participants.
In the Rasch measurement theory analysis, all items for four scales had ordered thresholds. The exception was the Early Life Impact of Treatment scale, where thresholds for seven of the 12 items were disordered. Specifically, participants
were not able to distinguish between the two middle response options (i.e., a little of the time and some of the time). To simplify the scoring and ensure that all items had ordered thresholds, we rescored all 12 items into three response options by collapsing into one category the two middle response options. Subsequent Rasch measurement theory analyses for this scale used the rescored data. Table 3 lists the summary fit statistics. A nonsignificant chi-square value was achieved for all five scales. This finding supported the data fit to the Rasch model for each scale. The Person Separation Index values for the five scales ranged from 0.81 to 0.90, indicating good reliability. Table 4 lists the individual item-fit statistics. Fit residuals for 37 of the 42 items were within the recommended criteria of −2.5 to +2.5. The five items that were found to fall marginally outside of the criteria range were retained, given that the other fit statistics were satisfied. The chi-square p values for all 42 items were nonsignificant, indicating good item fit.
Items within each of the five scales in Table 4 reflect the serial order of each scale. For example, in the Satisfaction with Outcome of Treatment scale, the easiest item for participants to strongly agree with was "I am pleased with the result," which had an item location of −1.15, and the hardest item for participants to strongly agree with was "The result is miraculous," which had an item location of 1.87. Tables 5 and 6 list the traditional psychometric results. The scale level Flesch-Kincaid grade ranged from 0 to 6. All scales exceeded criteria for acceptability, reliability, and validity. Cronbach alpha coefficients (≥0.90) and interitem correlations (≥0.43) supported scale reliability.
Scale validity was supported by the high Cronbach alpha coefficients and interscale correlations. The interscale correlations (Table 7) for four scales (exception, Early Life Impact of Treatment) were in the hypothesized range; these scales measured a distinct but clinically related variable.
The Early Life Impact of Treatment correlated less than 0.30 with the other scales, indicating that the construct measured by this scale was distinct. The correlations between the scales and participant characteristics were low, as predicted, suggesting that little bias was present.
The correlation between total number of symptoms experienced following treatment and the Early Life Impact of Treatment scores in the first week following treatment were strong, as predicted (lip filler participants, r = −0.66, p < 0.01; face-lift participants, r = −0.46, p < 0.01). Table 8 shows the proportion of participants to report being bothered by a symptom on the Recovery Early Symptom checklist. Common early (day 2) symptoms reported by face-lift participants included discomfort (96 percent), feeling your face is tight (95 percent), tenderness (91 percent), and numbness (loss of feeling) (90 percent). For lip filler participants, common early (day 1) symptoms included swelling (92 percent), tenderness (85 percent), discomfort (73 percent), and feeling sore (71 percent). Table 9 shows the responsiveness results. For the Early Life Impact of Treatment scale, for both face-lift and lip participants, a large improvement in scores was reported by face-lift participants between their first (day 3-5) and final (day 30) assessments (effect size, 1.7; standardized response mean, 1.5), and for lip treatment participants between day 1 and day 14 (effect size, 1.0; standardized response mean, 1.0). For lip treatment participants (first/last assessment = baseline/90 days) showed that there were moderate to large changes in the Psychological Wellbeing (effect size, 0.8; standardized response mean, 0.7) scale and moderate changes in the Social Function (effect size, 0.5; standardized response mean, 
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DISCUSSION
The FACE-Q is being developed and validated using a rigorous mixed methods approach to provide the research and clinical community with a comprehensive outcomes measurement system. Our goal in designing the FACE-Q was to address the lack of available patient-reported outcome tools applicable to facial aesthetics patients. As with previously published FACE-Q scales, 22, 23 the scales examined in the present article were found to be clinically meaningful, valid, and reliable. In addition, the Recovery Early Symptom checklist identified a range of postoperative symptoms following face lifts and lip treatment.
The scales were also responsive to clinical change following treatment. As would be expected, face-lift participants reported more early life impact compared with the lip treatment sample, although both groups showed clinically important change over the course of recovery. The trial data provide evidence that lip treatment has an effect on quality of life, with large (Psychological Wellbeing) and moderate (Social Function) effect sizes noted. Given the nature of minimally invasive lip treatments, which disappear gradually over time, Psychological Wellbeing, Social Function, and Satisfaction with Outcome of Treatment scores declined by day 90, as expected. Interestingly, participants' scores for Satisfaction with Decision to Have Treatment did not decline.
Although there is an ever-growing range of facial cosmetic products and treatments available, very little clinical research is being performed in either academia or industry to understand outcomes from the patient's perspective. This oversight is despite the fact that such information is exactly what potential consumers want and need to know (i.e., what other patients who have undergone facial aesthetics treatment experience). Furthermore, clinicians need such information to educate their patients about the benefits they may or may not derive from any particular treatment. As the cosmetics industry continues to grow and diversify, the application and use of patientreported outcome instruments in research needs to keep pace. The patient perspective in outcomes research is increasingly being taken seriously. 3 It is, after all, a crucial indicator of the success of aesthetic treatments and therefore should be routinely measured and reported. MID, minimum important difference; ES, effect size; SRM, standardized response mean. *The ES and SRM were computed to reflect the incremental change between assessment days. Positive ES and SRMs reflect an improvement in scale scores, whereas negative ES and SRMs represent a worsening in scale scores.
It is important to keep in mind limitations in our study design, which we have described previously and will review here in brief. First, plastic surgery and dermatology office staff invited an array of patients to complete the FACE-Q scales. An advantage to this recruitment strategy is that we are able to ensure that the final version of each scale is well-targeted to the general population of facial aesthetic patients rather than a subgroup of patients. The disadvantage is that our data set is not able to answer in a definitive way how patient outcomes relate to specific patient or clinical characteristics. Second, our sample is composed of more women than men and reflects the fact that facial aesthetics is still overwhelmingly pursued by women. Third, our response rate for the mailed survey portion of our study was lower than we would have liked but represents only a small proportion of the sample. Fourth, we acknowledge that there could have been some bias introduced at the individual clinic level by office staff who recruited their patients for us. For example, it is possible that staff may have overlooked "unsatisfied" clients in their recruitment. Future studies that recruit a consecutive sample of patients from a random sample of clinics would enable us to determine how well our scales' content is targeted to capturing the full range of experiences of cosmetic patients.
CONCLUSIONS
This new set of FACE-Q instruments can be smoothly incorporated into research and/or routine clinical practice to better understand the recovery process and quality-of-life impact of facial aesthetics procedures and what patients think about their decision to undergo surgery. As plastic surgeons seek to continually improve aesthetic outcomes alongside the patient experience, we envision that future studies implementing FACE-Q scales will contribute to a greater appreciation of comparative effectiveness between various new and existing techniques. 
